MX386328B - Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. - Google Patents
Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.Info
- Publication number
- MX386328B MX386328B MX2017012380A MX2017012380A MX386328B MX 386328 B MX386328 B MX 386328B MX 2017012380 A MX2017012380 A MX 2017012380A MX 2017012380 A MX2017012380 A MX 2017012380A MX 386328 B MX386328 B MX 386328B
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- methods
- maytansinoid derivatives
- maytansinoid
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139044P | 2015-03-27 | 2015-03-27 | |
| US201562252239P | 2015-11-06 | 2015-11-06 | |
| PCT/US2016/024343 WO2016160615A1 (en) | 2015-03-27 | 2016-03-25 | Maytansinoid derivatives, conjugates thereof, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012380A MX2017012380A (es) | 2018-04-11 |
| MX386328B true MX386328B (es) | 2025-03-18 |
Family
ID=55650789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012380A MX386328B (es) | 2015-03-27 | 2016-03-25 | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. |
| MX2021008101A MX2021008101A (es) | 2015-03-27 | 2017-09-27 | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008101A MX2021008101A (es) | 2015-03-27 | 2017-09-27 | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160375147A1 (enExample) |
| EP (1) | EP3273998B1 (enExample) |
| JP (2) | JP6948950B2 (enExample) |
| KR (2) | KR102708103B1 (enExample) |
| CN (2) | CN115645543A (enExample) |
| AU (1) | AU2016243527B2 (enExample) |
| BR (1) | BR112017020149A8 (enExample) |
| CA (1) | CA2978340C (enExample) |
| CL (1) | CL2017002422A1 (enExample) |
| CO (1) | CO2017010890A2 (enExample) |
| EA (1) | EA034950B1 (enExample) |
| IL (1) | IL254267B (enExample) |
| MX (2) | MX386328B (enExample) |
| PH (1) | PH12017501780A1 (enExample) |
| SG (1) | SG11201707148PA (enExample) |
| WO (1) | WO2016160615A1 (enExample) |
| ZA (1) | ZA201706040B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| EP3038624B1 (en) | 2013-08-26 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| SG11201707148PA (en) | 2015-03-27 | 2017-10-30 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2016205738A2 (en) | 2015-06-19 | 2016-12-22 | Cytrx Corporation | Delivery systems for controlled drug release |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| PH12018501589B1 (en) | 2016-01-25 | 2022-08-10 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| NZ751906A (en) | 2016-09-23 | 2025-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| PL3515946T3 (pl) | 2016-09-23 | 2022-11-07 | Regeneron Pharmaceuticals, Inc. | Przeciwciała anty-muc16 (mucyna 16) |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN110382534B (zh) | 2016-11-29 | 2023-05-09 | 里珍纳龙药品有限公司 | 治疗prlr阳性乳腺癌的方法 |
| JP7364471B2 (ja) | 2017-05-18 | 2023-10-18 | レゲネロン ファーマシューティカルス，インコーポレーテッド | シクロデキストリンタンパク質薬物コンジュゲート |
| MY198804A (en) | 2017-06-07 | 2023-09-28 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| CA3080857A1 (en) | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| US11572373B2 (en) * | 2017-11-30 | 2023-02-07 | Ladrx Corporation | Maytansinoid-based drug delivery systems |
| JP7328990B2 (ja) * | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用 |
| CN112135624B (zh) | 2018-05-17 | 2024-07-19 | 瑞泽恩制药公司 | 抗cd63抗体、缀合物和其用途 |
| WO2020057543A1 (zh) * | 2018-09-21 | 2020-03-26 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
| CN113727757A (zh) | 2019-02-21 | 2021-11-30 | 瑞泽恩制药公司 | 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| AU2020381495A1 (en) | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
| WO2021174113A1 (en) | 2020-02-28 | 2021-09-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| IL319200A (en) | 2020-04-16 | 2025-04-01 | Regeneron Pharma | Antibody-drug conjugates prepared using Diels-Alder compression methods |
| EP4232481A1 (en) | 2020-10-22 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr2 antibodies and methods of use thereof |
| IL302814A (en) | 2020-11-10 | 2023-07-01 | Regeneron Pharma | Selenium antibody conjugates |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| WO2006062779A2 (en) | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
| PL2135881T3 (pl) | 2005-06-20 | 2012-02-29 | Genentech Inc | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu |
| CN101287498B (zh) | 2005-06-20 | 2013-03-27 | Psma开发有限公司 | Psma抗体-药物缀合物 |
| CA2617953C (en) | 2005-08-09 | 2013-12-17 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
| BRPI0620434A2 (pt) | 2005-12-22 | 2011-11-16 | Baxter Int | teste aperfeiçoado de ativação de monócitos capaz de detectar melhor contaminantes pirogênicos não-endotóxicos em produtos médicos |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| RU2483080C2 (ru) | 2006-10-27 | 2013-05-27 | Дженентек, Инк. | Антитела и иммуноконъюгаты и их применение |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| KR20160125535A (ko) | 2008-03-18 | 2016-10-31 | 제넨테크, 인크. | 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| DK2374481T3 (en) | 2008-07-21 | 2016-02-01 | Polytherics Ltd | New reagents and methods for the conjugation of biological molecules |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CN102597773B (zh) | 2009-08-10 | 2015-07-15 | Ucl商业有限公司 | 功能性分子的可逆的共价连接 |
| AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| RS52983B (sr) | 2010-04-15 | 2014-02-28 | Spirogen Sárl | Pirolobenzodiazepini i njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| RS55495B1 (sr) | 2010-08-02 | 2017-04-28 | Regeneron Pharma | Miševi koji stvaraju vezujuće proteine koji sadrže vl domene |
| BR112013005070B1 (pt) | 2010-09-01 | 2018-04-03 | Bayer Intellectual Property Gmbh | Compostos n-(tetrazol-5-il)- e n-(triazol-5-il) arilcarboxamidas, composição herbicida, seus usos como herbicidas e método para controlar plantas indesejadas |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| CA2816681A1 (en) | 2010-11-03 | 2012-05-10 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
| CN103732256A (zh) | 2011-05-16 | 2014-04-16 | 皇家飞利浦有限公司 | 生物正交药物活化 |
| EP3170821B1 (en) | 2011-05-27 | 2021-09-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EA029797B1 (ru) * | 2011-06-21 | 2018-05-31 | Иммуноджен, Инк. | Новые производные майтанзиноида с пептидным линкером и их конъюгаты |
| WO2013053872A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| JP6399930B2 (ja) | 2011-10-14 | 2018-10-03 | シアトル ジェネティクス，インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| JP6170497B2 (ja) | 2011-10-14 | 2017-07-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| SG11201402686UA (en) | 2011-12-05 | 2014-06-27 | Igenica Inc | Antibody-drug conjugates and related compounds, compositions, and methods |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| IN2014DN10428A (enExample) | 2012-06-19 | 2015-08-21 | Polytherics Ltd | |
| RS64329B1 (sr) | 2012-10-23 | 2023-08-31 | Synaffix Bv | Modifikovano antitelo, konjugat antitela i postupak za njihovo pripremanje |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| AU2012395148B2 (en) * | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103333179B (zh) | 2012-12-21 | 2017-06-16 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| NZ714765A (en) | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| EP3038624B1 (en) | 2013-08-26 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| WO2015081281A1 (en) | 2013-11-26 | 2015-06-04 | Segway Orthopaedics, Inc. | Surgical blade with viewing aperture |
| US9493413B2 (en) | 2013-11-27 | 2016-11-15 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| CN105793268B (zh) | 2013-12-02 | 2019-03-15 | 香港浸会大学 | 具有两个稠合大环的抗癌性美登木素类化合物 |
| EP3148592A2 (en) | 2014-06-02 | 2017-04-05 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| SG11201707148PA (en) * | 2015-03-27 | 2017-10-30 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| PH12018501589B1 (en) | 2016-01-25 | 2022-08-10 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| NZ751906A (en) | 2016-09-23 | 2025-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2016
- 2016-03-25 SG SG11201707148PA patent/SG11201707148PA/en unknown
- 2016-03-25 CA CA2978340A patent/CA2978340C/en active Active
- 2016-03-25 EA EA201700464A patent/EA034950B1/ru unknown
- 2016-03-25 AU AU2016243527A patent/AU2016243527B2/en active Active
- 2016-03-25 KR KR1020177030678A patent/KR102708103B1/ko active Active
- 2016-03-25 EP EP16714199.3A patent/EP3273998B1/en active Active
- 2016-03-25 BR BR112017020149A patent/BR112017020149A8/pt not_active Application Discontinuation
- 2016-03-25 JP JP2017550548A patent/JP6948950B2/ja active Active
- 2016-03-25 CN CN202210829028.0A patent/CN115645543A/zh active Pending
- 2016-03-25 MX MX2017012380A patent/MX386328B/es unknown
- 2016-03-25 US US15/081,759 patent/US20160375147A1/en not_active Abandoned
- 2016-03-25 CN CN201680030443.2A patent/CN107995912A/zh active Pending
- 2016-03-25 WO PCT/US2016/024343 patent/WO2016160615A1/en not_active Ceased
- 2016-03-25 KR KR1020247030839A patent/KR20240142591A/ko active Pending
-
2017
- 2017-09-01 IL IL254267A patent/IL254267B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06040A patent/ZA201706040B/en unknown
- 2017-09-26 CL CL2017002422A patent/CL2017002422A1/es unknown
- 2017-09-27 PH PH12017501780A patent/PH12017501780A1/en unknown
- 2017-09-27 MX MX2021008101A patent/MX2021008101A/es unknown
- 2017-10-26 CO CONC2017/0010890A patent/CO2017010890A2/es unknown
-
2019
- 2019-12-12 US US16/712,941 patent/US20200385402A1/en not_active Abandoned
-
2021
- 2021-03-17 JP JP2021044152A patent/JP2021113191A/ja not_active Withdrawn
- 2021-11-16 US US17/528,144 patent/US12297207B2/en active Active
-
2025
- 2025-03-28 US US19/093,440 patent/US20250223299A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386328B (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| MX390630B (es) | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. | |
| CL2018000813A1 (es) | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso. | |
| MX2016014247A (es) | Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7). | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| MX374788B (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| BR112016024525A2 (pt) | novos anticorpos anti-rnf43 e métodos de uso | |
| MX2016009862A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
| BR112016013048A2 (pt) | anticorpos anti-dpep3 e métodos de uso | |
| PH12018501153A1 (en) | Novel anti-claudin antibodies and methods of use | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| IL261920A (en) | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| BR112018012883A2 (pt) | novos anticorpos anti-upk1b e métodos de uso | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso | |
| NI201500033S (es) | Chainsaw ms382-1119 |